FMR LLC - Y-MABS THERAPEUTICS INC ownership

Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 100 filers reported holding Y-MABS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
FMR LLC ownership history of Y-MABS THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$196,609
-21.7%
36,075
-2.4%
0.00%
Q2 2023$251,040
+1812.5%
36,972
+1311.1%
0.00%
Q1 2023$13,126
+123.8%
2,620
+118.0%
0.00%
Q4 2022$5,866
-100.0%
1,202
-99.9%
0.00%
-100.0%
Q3 2022$19,877,000
-33.3%
1,378,466
-30.1%
0.00%
-33.3%
Q2 2022$29,819,000
+27.4%
1,970,851
+0.0%
0.00%
+50.0%
Q1 2022$23,407,000
-5.4%
1,970,268
+29.1%
0.00%0.0%
Q4 2021$24,733,000
-43.2%
1,525,7870.0%0.00%
-33.3%
Q3 2021$43,546,000
-16.8%
1,525,787
-1.5%
0.00%
-25.0%
Q2 2021$52,356,000
+11.8%
1,548,9870.0%0.00%0.0%
Q1 2021$46,841,000
-6.1%
1,548,987
+53.8%
0.00%0.0%
Q4 2020$49,865,000
+16.5%
1,007,174
-9.6%
0.00%0.0%
Q3 2020$42,791,000
-24.4%
1,114,642
-15.0%
0.00%
-33.3%
Q2 2020$56,624,000
+56.0%
1,310,742
-5.8%
0.01%
+20.0%
Q1 2020$36,301,000
-16.5%
1,390,842
-0.0%
0.01%0.0%
Q4 2019$43,471,000
+2.6%
1,391,061
-14.5%
0.01%0.0%
Q3 2019$42,390,000
+13.9%
1,626,6420.0%0.01%
+25.0%
Q2 2019$37,201,000
-12.7%
1,626,6420.0%0.00%
-20.0%
Q1 2019$42,634,000
+28.9%
1,626,6420.0%0.01%0.0%
Q4 2018$33,086,000
+1.2%
1,626,642
+32.2%
0.01%
+25.0%
Q3 2018$32,686,0001,230,6420.00%
Other shareholders
Y-MABS THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Memorial Sloan Kettering Cancer Center 191,176$1,041,9094.24%
Sofinnova Investments, Inc. 2,194,278$11,958,8150.75%
DENALI ADVISORS LLC 85,900$468,1550.16%
Polar Capital Holdings Plc 2,103,298$11,462,9740.08%
Soleus Capital Management, L.P. 157,182$856,6420.08%
GSA CAPITAL PARTNERS LLP 137,299$7480.06%
Caligan Partners LP 23,321$127,0990.06%
Corton Capital Inc. 12,244$66,7300.03%
RICE HALL JAMES & ASSOCIATES, LLC 91,249$497,3070.03%
CIM INVESTMENT MANAGEMENT INC 15,313$83,4560.03%
View complete list of Y-MABS THERAPEUTICS INC shareholders